---
title: "Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 | HRMY Stock News"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275463934.md"
description: "Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will report its fourth quarter and full year 2025 financial results on February 24, 2026, before U.S. markets open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. Participants can join by calling 800-274-7083 (domestic) or 203-518-9786 (international) with passcode HRMYQ425. Harmony Biosciences focuses on developing therapies for rare neurological diseases."
datetime: "2026-02-10T05:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275463934.md)
  - [en](https://longbridge.com/en/news/275463934.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275463934.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275463934.md) | [English](https://longbridge.com/en/news/275463934.md)


# Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 | HRMY Stock News

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 24, 2026, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial 800-274-7083 (domestic) or 203-518-9786 (international), and reference passcode HRMYQ425. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

**About Harmony Biosciences**

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260210287847/en/

**Investor Contact:  
**Matthew Beck  
astr partners  
917-415-1750  
matthew.beck@astrpartners.com

**Media Contact:**  
Cate McCanless  
Harmony Biosciences  
202-641-6086  
cmccanless@harmonybiosciences.com

Source: Harmony Biosciences Holdings, Inc.

### 相關股票

- [Harmony Biosciences (HRMY.US)](https://longbridge.com/zh-HK/quote/HRMY.US.md)

## 相關資訊與研究

- [Harmony Biosciences Holdings, Inc. $HRMY Shares Acquired by American Century Companies Inc.](https://longbridge.com/zh-HK/news/278051989.md)
- [Is Harmony Biosciences (HRMY) Pricing Reflect Recent Share Slump And DCF Upside Potential](https://longbridge.com/zh-HK/news/276681279.md)
- [Harmony Biosciences Hldgs Earnings Review: Q4 Summary](https://longbridge.com/zh-HK/news/276734442.md)
- [UBS Group Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $36.00](https://longbridge.com/zh-HK/news/276935717.md)
- [Sandip Kapadia Sells 3,746 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock](https://longbridge.com/zh-HK/news/274076411.md)